

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF THE COMPANY AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX

This announcement is made voluntarily by Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) to inform shareholders and potential investors of the latest business developments of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that, pursuant to the results of the quarterly review of the Hang Seng Family of Indexes for the period ended December 31, 2025 announced by Hang Seng Indexes Company Limited on February 13, 2026, the Company has been included as a constituent stock of the Hang Seng Composite Index. The adjustment will take effect on March 9, 2026.

The Hang Seng Composite Index, as a comprehensive benchmark for Hong Kong stocks, comprehensively covers the top 95% of listed companies on the Main Board of the Hong Kong Stock Exchange by cumulative market capitalization. Inclusion as a constituent of the Hang Seng Composite Index is expected to render the Company’s shares eligible for inclusion under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect which act as a channel for share trading and investment between capital market investors in Hong Kong and mainland China.

The Board believes that the inclusion of the Company as a constituent of the Hang Seng Composite Index reflects investors’ recognition of the Company’s value and growth potential. The Board anticipates that this inclusion is expected to enhance the liquidity of the Company’s shares, broaden the investor base, and enrich the shareholder structure. This will further elevate the Company’s reputation and investment value in the capital markets, benefiting its long-term stable development.

The Board extends its sincere gratitude to all shareholders, investors, and partners for their long-standing trust and support. The Company will continue to strive for business development and create value for shareholders.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm is an innovative pharmaceutical company rooted in China with a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development (“**R&D**”), production and commercialization of class 1 drugs with core proprietary intellectual property rights. The Company has a first-class R&D team that all core personnel have years of experience in new drug R&D. The Company has two R&D platforms: small molecule chemistry and large molecule biopharmaceuticals. The dual engines drive the Company’s innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the Company is committed to developing into a first-class innovative pharmaceutical company with independent R&D, production, and sales capabilities.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, February 22, 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.